Reaction Biology, Cisbio Ink Deal for Distribution of Epigenetic Proteins | GenomeWeb

NEW YORK (GenomeWeb News) – Contract research organization Reaction Biology (RBC) said today that it has signed an agreement with Cisbio Bioassays for distribution of its epigenetic proteins.

The agreement gives Cisbio global rights to co-market and sell RBC's epigenetic proteins. Cisbio can include these proteins in its portfolio of assays, including recently added assays for assessing epigenetic targets like methyltransferases.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PNAS this week: carbapenem resistance in Enterobacteriaceae, selection against educational attainment-linked variants, and more.

Technology Review points out that a new US presidential science advisor hasn't been selected.

Researchers find that blood tests might be able to help determine severity of a concussion, Wired reports.

President-elect Donald Trump considers other candidates for director of the National Institutes of Health, Nature News reports.